About Cellectar Biosciences
Cellectar Biosciences is a company based in Florham Park (United States) founded in 2002 was acquired by Novelos Therapeutics in April 2011. The company has 11 employees as of December 31, 2024. Cellectar Biosciences operates in a competitive market with competitors including Insulet, Lyra Therapeutics, TriSalus Life Sciences, Credence MedSystems and Foresee Pharmaceuticals, among others.
- Headquarter Florham Park, United States
- Employees 11 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cellectar Biosciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$44.58 M (USD)-4.23as on Dec 31, 2024
-
EBITDA
-$51.49 M (USD)-32.8as on Dec 31, 2024
-
Latest Funding Round
$24.5 M (USD), Post-IPO
Sep 05, 2023
-
Investors
HHS
& 10 more
-
Employee Count
11
as on Dec 31, 2024
-
Acquired by
Novelos Therapeutics
(Apr 11, 2011)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Cellectar Biosciences
Cellectar Biosciences is a publicly listed company on the NASDAQ with ticker symbol CLRB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Cellectar Biosciences
Unlock access to complete
Unlock access to complete
Funding Insights of Cellectar Biosciences
Investors in Cellectar Biosciences
Cellectar Biosciences has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, National Cancer Institute and Novelos Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Multiple sectors focused seed & early stage VC firm investing in the US, Europe & Asia
|
Locked | Locked | Locked | |
|
Private equity investment firm
|
Locked | Locked | Locked |
Investor details for Cellectar Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cellectar Biosciences
Investment portfolio details for Cellectar Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cellectar Biosciences
Detailed financials for Cellectar Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellectar Biosciences Comparisons
Peer comparison for Cellectar Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cellectar Biosciences
Cellectar Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insulet, Lyra Therapeutics, TriSalus Life Sciences, Credence MedSystems and Foresee Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Wearable insulin infusion systems are developed for diabetes patients.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for ENT diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of drug delivery devices to treat cancers
|
|
| Locked | Locked | Locked |
Developer of smart devices for drug delivery
|
|
| Locked | Locked | Locked |
Injectables and NCEs for cancer and chronic diseases are developed.
|
Detailed competitors of Cellectar Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellectar Biosciences
Complete news archive for Cellectar Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellectar Biosciences
Cellectar Biosciences was founded in 2002 and raised its 1st funding round 6 years after it was founded.
Cellectar Biosciences is headquartered in Florham Park, United States. It is registered at Florham Park, New Jersey, United States.
As of Dec 31, 2024, the latest employee count at Cellectar Biosciences is 11.
Founded in 2002 and based in Florham Park, United States, phospholipid drug conjugates are developed by the biotechnology firm for oncology applications. The lead product, CLR 131, incorporates iodine-131 to damage cancer cell DNA, while another variant targets solid tumors by arresting the cell cycle. Additional conjugates, such as CLR 1602-PTX for paclitaxel delivery, are pursued using a proprietary phospholipid ether platform that enables targeted drug transport to cancer cells.
Cellectar Biosciences's top competitors include Insulet, Lyra Therapeutics and TriSalus Life Sciences.
Yes, Cellectar Biosciences is publicly traded on NASDAQ under the ticker symbol CLRB.
Cellectar Biosciences has 11 investors. Key investors include HHS, National Cancer Institute, Novelos Therapeutics, Rosalind Advisors, and AIGH Capital Management.
The ticker symbol of Cellectar Biosciences is CLRB on NASDAQ.